PBYI — Puma Biotechnology Share Price
0.000.00%
Last trade - 00:00- $148.83m
- $114.92m
- $230.47m
- 77
- 96
- 88
- 99
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 8.03 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -31.8% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.62 | ||
| Price to Tang. Book | 3.63 | ||
| Price to Free Cashflow | 3.83 | ||
| Price to Sales | 0.65 | ||
| EV to EBITDA | 2.7 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 26.42% | ||
| Return on Equity | 41.6% | ||
| Operating Margin | 13.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 225.11 | 253.16 | 228.03 | 235.64 | 230.47 | 217.8 | 212.53 | -3.28% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +158.87 | +32.16 | -35.13 | -20.75 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
Directors
- Alan Auerbach CHM (51)
- Maximo Nougues CFO (52)
- Douglas Hunt SVP (56)
- Jeff Ludwig OTH (55)
- Jay Moyes LED (67)
- Allison Dorval DRC (46)
- Michael Miller IND (64)
- Adrian Senderowicz IND (57)
- Brian Stuglik IND (62)
- Troy Wilson IND (52)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 15th, 2010
- Public Since
- March 21st, 2012
- No. of Shareholders
- 9
- No. of Employees
- 172
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 49,610,799
- Address
- 10880 Wilshire Blvd., Suite 2150, LOS ANGELES, 90024
- Web
- https://www.pumabiotechnology.com/
- Phone
- +1 4242486500
- Contact
- Mariann Ohanesian
- Auditors
- KPMG LLP
Upcoming Events for PBYI
Q1 2025 Puma Biotechnology Inc Earnings Call
Puma Biotechnology Inc Annual Shareholders Meeting
Q2 2025 Puma Biotechnology Inc Earnings Release
Similar to PBYI
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Puma Biotechnology share price?
As of Today at 22:46 UTC, shares in Puma Biotechnology are trading at $3.00. This share price information is delayed by 15 minutes.
How has the Puma Biotechnology share price performed this year?
Shares in Puma Biotechnology last closed at $3.00 and the price had moved by -38.52% over the past 365 days. In terms of relative price strength the Puma Biotechnology share price has underperformed the S&P500 Index by -43.26% over the past year.
What are the analyst and broker recommendations for Puma Biotechnology?
The overall consensus recommendation for Puma Biotechnology is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Puma Biotechnology dividend yield?
Puma Biotechnology does not currently pay a dividend.
Does Puma Biotechnology pay a dividend?
Puma Biotechnology does not currently pay a dividend.
When does Puma Biotechnology next pay dividends?
Puma Biotechnology does not currently pay a dividend.
How do I buy Puma Biotechnology shares?
To buy shares in Puma Biotechnology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Puma Biotechnology?
As of the previous close price of $3.00, shares in Puma Biotechnology had a market capitalisation of $148.83m.
Where are Puma Biotechnology shares listed?
Here are the trading details for Puma Biotechnology:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PBYI
What kind of share is Puma Biotechnology?
Based on an overall assessment of its quality, value and momentum Puma Biotechnology is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Puma Biotechnology share price forecast for 2025?
The analyst consensus target price for shares in Puma Biotechnology is $4.33. That is 44.33% above the last closing price of $3.00.
Analysts covering Puma Biotechnology currently have a consensus Earnings Per Share (EPS) forecast of $0.40 for the next financial year.
Find out moreWhat is the trend in the Puma Biotechnology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Puma Biotechnology. Over the past six months, its share price has outperformed the S&P500 Index by +7.19%.
As of the last closing price of $3.00, shares in Puma Biotechnology were trading -0.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Puma Biotechnology PE Ratio?
The Puma Biotechnology PE ratio based on its reported earnings over the past 12 months is 8.03. The shares last closed at $3.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Puma Biotechnology?
Puma Biotechnology's management team is headed by:
- Alan Auerbach - CHM
- Maximo Nougues - CFO
- Douglas Hunt - SVP
- Jeff Ludwig - OTH
- Jay Moyes - LED
- Allison Dorval - DRC
- Michael Miller - IND
- Adrian Senderowicz - IND
- Brian Stuglik - IND
- Troy Wilson - IND